

ASX Announcement

Completion of Share Purchase Plan Offer

SYDNEY Australia 23 October 2017: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced the successful completion of its Share Purchase Plan Offer (**SPP Offer**) of new fully paid ordinary shares at \$0.175 per share (**New Shares**).

The SPP Offer closed at 5.00pm (AEDST) on Wednesday, 18 October 2017. The Board has taken the decision to accept all valid applications. Recce has accepted applications from 171 registered shareholders totalling \$946,500, equivalent to 5,408,487 New Shares.

Recce Executive Chairman Dr Graham Melrose said: “We are encouraged by the strong support received from our shareholders”.

The New Shares are expected to be issued on Wednesday, 25 October 2017, with holding statements expected to be despatched to participating shareholders on Thursday, 26 October 2017.

About Recce Ltd

Recce Limited (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 is being developed for the treatment of sepsis derived from *S. aureus* and *E. coli* bacteria – including their superbug forms. Pre-clinical testing in laboratory and animal models has demonstrated positive results to date. Recce has a manufacturing facility in Australia and clinical research partners in the USA. It has validated an automated process to manufacture its lead compound ahead of first-in-man clinical trials.



ASX: RCE

Head Office - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Sydney Office Level 34, 50 Bridge Street, AMP Centre, SYDNEY NSW 2000 **T** +61 (0)2 8216 0768 **F** +61 (0)2 8216 0701

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

To receive the latest information on Recce - [Subscribe here](#)

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams

CFO & Company Secretary

Recce Ltd

Tel: (08) 9253 9800

Media (Australia)

Andrew Geddes

CityPR

Tel: (02) 9267 4511

Media (International)

Sue Charles/Gemma Harris

Instinctif Partners

Tel: +44 (0)20 7866 7860

E: recce@instinctif.com

